Moreover, the level of overexpression of HER3 in tumors is relatively low, generally not exceeding 50,000 receptors/cell [4] (for reference, breast cancer patients are considered HER2+ with expression >2.3 × 106 receptors/cell [5]). This evidence concerns the gene ERBB2 and breast cancer.